OR WAIT 15 SECS
Applied Biosystems announced at the 2006 Annual Meeting of the American Association for Cancer Research...
Applied Biosystems announced at the 2006 Annual Meeting of the American Association for Cancer Research (AACR) that it has entered into a collaboration agreement with the Core Genotyping Facility, SAIC-Frederick, a contractor for the National Cancer Institute (NCI). The companies will work together on a series of biomarker studies for cancer research.
The NCI-funded core genotyping facility will use Applied Biosystems' entire TaqMan Drug Metabolism Genotyping Assay collection to examine genetic variations in the HapMap and SNP500Cancer samples to validate additional cancer biomarkers. More than 2400 TaqMan Drug metabolism Genotyping Assays will be used by the facility to generate the genotypes for samples from the International HapMap Project and from NCI's SNP500Cancer standard sample panel. Additionally, select assays with significant data correlation from data analysis will be used to genotype individuals who participated in a pharmacogenetic study at the NCI evaluating treatment for Non-Hodgkin lymphoma.